MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.09
-0.06
-0.31%
Closed 16:11 11/20 EST
OPEN
19.10
PREV CLOSE
19.15
HIGH
19.52
LOW
18.87
VOLUME
2.20M
TURNOVER
--
52 WEEK HIGH
19.39
52 WEEK LOW
13.24
MARKET CAP
2.80B
P/E (TTM)
-69.5953
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of HALO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

HALO News

  • Cantor Fitzgerald Reiterates Overweight on Halozyme Therapeutics, Raises Price Target to $27
  • Benzinga.21h ago
  • The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
  • Benzinga.21h ago
  • Edited Transcript of HALO earnings conference call or presentation 12-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.2d ago
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.5d ago

More

Industry

Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About HALO

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
More

Webull offers Halozyme Therapeutics, Inc. (HALO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.